Citations

Showing 10 of 108119 citations.

Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
Hilal, Talal , Sonbol, Mohamad Bassam , Sonbol, Mohamad B , Hilal, Talal , Prasad, Vinay K.

Mayo Clinic

JAMA Oncology | May 2, 2019 | Volume: 5 | Issue: 6 | Pages: 887

10.1001/jamaoncol.2019.0167 | PMID 31046071 Get It

Qualitative Research Methods in Medical Education
Sawatsky, Adam P. , Ratelle, John T. , Beckman, Thomas J.

Mayo Clinic

Anesthesiology | May 2, 2019 | Volume: 131 | Issue: 1 | Pages: 14-22

10.1097/aln.0000000000002728 | PMID 31045898 Get It

Abstract Qualitative research was originally developed within the social sciences. Medical education is a field that comprises multiple disciplines, including the social sciences, and utilizes qualitative research to gain a broader understanding of key phenomena within the field. Many clinician educators are unfamiliar with qualitative research. This article provides a primer for clinician educators who want to appraise or conduct qualitative research in medical education. This article discusses a definition and the philosophical underpinnings for qualitative research. Using the Standards for Reporting Qualitative Research as a guide, this article provides a step-wise approach for conducting and evaluating qualitative research in medical education. This review will enable the reader to understand when to utilize qualitative research in medical education and how to interpret reports using qualitative approaches.
Quantitative Research Methods in Medical Education
Ratelle, John T. , Sawatsky, Adam P. , Beckman, Thomas J.

Mayo Clinic

Anesthesiology | May 2, 2019 | Volume: 131 | Issue: 1 | Pages: 23-35

10.1097/aln.0000000000002727 | PMID 31045900 Get It

Abstract There has been a dramatic growth of scholarly articles in medical education in recent years. Evaluating medical education research requires specific orientation to issues related to format and content. Our goal is to review the quantitative aspects of research in medical education so that clinicians may understand these articles with respect to framing the study, recognizing methodologic issues, and utilizing instruments for evaluating the quality of medical education research. This review can be used both as a tool when appraising medical education research articles and as a primer for clinicians interested in pursuing scholarship in medical education.
Late-onset Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes Presenting With Auditory Agnosia
Chiu, Shannon , Chandregowda, Adithya , Babovic‐Vuksanovic, Dusica , Babovic-Vuksanovic, Dusica, Smith, Kelsey M. , Hunt, Christopher H. , Keegan, B. Mark

Mayo Clinic

The Neurologist | May 2, 2019 | Volume: 24 | Issue: 3 | Pages: 90-92

10.1097/nrl.0000000000000229 | PMID 31045719 Get It

Introduction: Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a multisystemic mitochondrial disorder that usually presents in childhood. Patients can have a wide array of neurological symptoms when presenting with stroke-like episodes, and imaging characteristics during the episodes can overlap with different neurological disorders. Case Report: A 61-year-old woman presented with communication difficulties consistent with auditory agnosia and was found to have bitemporal abnormalities on imaging that first raised the concern for herpes simplex virus encephalitis. Further work-up, in conjunction with the patient’s past medical and family history, suggested a mitochondrial disorder. Mitochondrial full genome analysis revealed m.3243A>G variant in the MT-TL1 gene, with 6% heteroplasmy in blood leading to a diagnosis of MELAS. Conclusions: MELAS is a disorder with clinical variability. Neuroimaging studies during stroke-like episodes in MELAS can provide significant clues to the underlying disorder. Although patients typically present in childhood, the first stroke-like episode can occur later in life in some patients, potentially related to a lower heteroplasmy level.
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma
Carabenciov, Ivan D. , Uhm, Joon H. , Ruff, Michael W. , Bhargav, Adip G.

Mayo Clinic

The Neurologist | May 2, 2019 | Volume: 24 | Issue: 3 | Pages: 87-89

10.1097/nrl.0000000000000227 | PMID 31045718 Get It

Pilocytic astrocytomas (PA) are highly vascular tumors with vascular endothelial growth factor (VEGF)–vascular endothelial growth factor receptor-2 (VEGFR-2) signaling present in the tumor vasculature. PA may, therefore, be responsive to VEGF blockade with bevacizumab (BEV). Data regarding the use of BEV in refractory PA in adults are limited primarily to case reports and case series of patients with recurrent PA. We conducted a single-center, retrospective cohort study from 2009 to 2018. We screened 426 patients with pathologically confirmed PA. We identified 5 adult patients with PA who received BEV at our institution with sufficient clinical follow-up to derive evidence of the efficacy and toxicity. All 5 patients experienced tumor progression after initial therapies which included surgery, radiation, and chemotherapy. Four patients received BEV as monotherapy, whereas 1 received BEV with the continuation of previously initiated alkylating chemotherapy (temozolomide). The average duration of BEV therapy was 10.2 months (range, 1 to 20 mo) with an average follow-up of 47 months (range, 6 to 112 mo). One patient had a severe necrotizing rash in areas of skin contact and discontinued after 1 cycle of BEV. All patients had stabilization per RANO criteria, with 1 patient experiencing progression after 10 months on treatment. One patient had disease progression 5 years after completion of BEV, but the tumor responded to repeat treatment with BEV. Our institution’s experience with the use of BEV in recurrent PA is in line with previous reports of therapeutic benefit in recurrent adult PA.
Localizing Epileptogenic Regions Using High-Frequency Oscillations and Machine Learning
Weiss, Shennan A. , Waldman, Zachary, Raimondo, Federico , Bragin, Anatol , Engel, Jerome , Staba, Richard J. , Sperling, Michael R. , Sperling, Michael R , Weiss, Shennan A , Slezak, Diego Fernández , Donmez, Mustafa, Worrell, Gregory A.

Mayo Clinic

Biomarkers in Medicine | May 2, 2019 | Volume: 13 | Issue: 5 | Pages: 409-418

10.2217/bmm-2018-0335 | PMID 31044598 Get It

Faculty Opinions recommendation of Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735470016.793559316 Get It

Faculty Opinions recommendation of Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Ansell, Stephen M.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735447544.793559317 Get It

Brain atrophy in primary age‐related tauopathy is linked to transactive response DNA‐binding protein of 43 kDa
Josephs, Keith A. , Murray, Melissa E. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Jack, Clifford R. , Whitwell, Jennifer L. , Jack, Clifford R , Murray, Melissa E , Knopman, David S. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | May 2, 2019 | Volume: 15 | Issue: 6 | Pages: 799-806

10.1016/j.jalz.2019.03.003 | PMID 31056344 Get It

AbstractIntroductionPrimary age‐related tauopathy (PART) is characterized by the presence of neurofibrillary tangles and absent‐minimal β‐amyloid deposition. Transactive response DNA‐binding protein of 43 kDa (TDP‐43), a third protein, has recently garnished a lot of attention in Alzheimer's disease where it is associated with memory loss and amygdala and hippocampal atrophy. We aimed to determine whether TDP‐43 is associated with brain atrophy in PART.MethodsWe assessed the frequency of TDP‐43 in PART and performed voxel‐level analysis in SPM12, as well as region‐of‐interest analysis using linear regression modeling, controlling for variables of interest, to assess for associations between TDP‐43 and brain atrophy.ResultsOf 116 PART cases, 31 (26.7%) had TDP‐43. The presence of TDP‐43 was associated with significantly greater amygdala, hippocampal, and anterior temporal atrophy in both the region‐of‐interest and the voxel level analyses.DiscussionTDP‐43 is associated with greater brain atrophy in PART.
Total Hip Arthroplasty in Patients with Spasticity
Statz, Joseph M. , Sierra, Rafael J. , Trousdale, Robert T. , Milbrandt, Todd A. , Sierra, Rafael J

Mayo Clinic

JBJS Reviews | May 2, 2019 | Volume: 7 | Issue: 4 | Pages: e10-e10

10.2106/jbjs.rvw.18.00115 | PMID 31045687 Get It

» Patients with neuromuscular spasticity about the hip with concomitant painful hip arthritis can be effectively treated with total hip arthroplasty, with excellent clinical outcomes and durable implant survivorship. » Certain subsets of patients in this population are at increased risk of dislocation, component loosening, and heterotopic ossification and are also prone to postoperative medical complications. » Strategies that may mitigate the risk of dislocation include using large femoral heads or dual-mobility articulations with cautious use of constrained liners, careful repairing of soft-tissue structures at the conclusion of the surgical procedure, and performing concomitant adductor and flexor tenotomies. In addition, the other common complications can be reduced by coordinating perioperative care with neurological and medical specialists and administering perioperative heterotopic ossification prophylaxis, most commonly in the form of nonsteroidal anti-inflammatory medications, if tolerated.